Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review

被引:3
作者
Fernandez-Guarino, Montserrat [1 ]
Ortiz, Pablo [2 ]
Gallardo, Fernando [3 ]
Llamas-Velasco, Mar [4 ]
机构
[1] Hosp Univ Ramon & Cajal, Dermatol Dept, Inst Invest Sanitaria Ramon & Cajal Irycis, Madrid 28034, Spain
[2] Hosp 12 Octubre, Dept Dermatol, Madrid 28041, Spain
[3] Hosp Mar, Dept Rheumatol, Barcelona 08003, Spain
[4] Hosp Univ Princesa, Fdn Invest Biomed Princesa, Dermatol Dept, Madrid 28006, Spain
关键词
cutaneous T-cell lymphoma; effectiveness; mogamulizumab; peripheral T-cell lymphoma; T-CELL LEUKEMIA; MONOCLONAL-ANTIBODY MOGAMULIZUMAB; MYCOSIS-FUNGOIDES; LENALIDOMIDE MAINTENANCE; ANTI-CCR4; ANTIBODY; EFFECTOR FUNCTIONS; MULTIPLE-MYELOMA; PROGNOSTIC INDEX; LYMPHOMA; VITILIGO;
D O I
10.3390/ijms25042203
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mogamulizumab (MOG) is an antibody targeting the CCR4 receptor, authorized for relapsed or refractory peripheral T-cell (PTCL) and cutaneous T-cell lymphomas (CTCL). Its adoption in guidelines and endorsement by FDA and EMA established it as a systemic treatment, especially for advanced disease stages due to its comparatively lower toxicity. Clinical trials and real-world evidence have underscored its efficacy in advanced CTCLs, including mycosis fungoides and Sezary syndrome; PTCLs; and adult T-cell leukemia/lymphoma (ATLL), showcasing positive outcomes. Notably, the drug has demonstrated significant response rates, disease stability, and extended periods of progression-free survival, suggesting its applicability in cases with multiple treatment lines. Its safety profile is generally manageable, with adverse events (AEs) primarily related to the skin, infusion-related reactions, drug eruptions, autoimmune diseases, and skin disorders. The latter seem to appear as CCR4 can promote the skin-specific homing of lymphocytes, and MOG is directed against this receptor. While combination with immunostimulatory agents like interferon alpha and interleukin 12 has shown promising results, caution is urged when combining with PD1 inhibitors due to the heightened risk of immune-mediated AEs. The introduction of MOG as a systemic treatment implies a significant advancement in managing these diseases, supported by its favorable safety profile and complementary mechanisms.
引用
收藏
页数:21
相关论文
共 112 条
  • [1] GENERALIZED VITILIGO FOLLOWING SEZARY-SYNDROME
    ALCALAY, J
    DAVID, M
    SHOHAT, B
    SANDBANK, M
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1987, 116 (06) : 851 - 855
  • [2] Mogamulizumab-induced vitiligo in patients with Sezary syndrome: three cases
    Algarni, Abdullah S.
    Ram-Wolff, Caroline
    Bagot, Martine
    De Masson, Adele
    [J]. EUROPEAN JOURNAL OF DERMATOLOGY, 2021, 31 (02) : 213 - 216
  • [3] Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation
    Alsina, Melissa
    Becker, Pamela S.
    Zhong, Xiaobo
    Adams, Alexia
    Hari, Parameswaran
    Rowley, Scott
    Stadtmauer, Edward A.
    Vesole, David H.
    Logan, Brent
    Weisdorf, Daniel
    Qazilbash, Muzaffar
    Popplewell, Leslie L.
    McClune, Brian
    Bensinger, William
    Riches, Marcie
    Giralt, Sergio A.
    Pasquini, Marcelo C.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (08) : 1183 - 1189
  • [4] Cutaneous T cell lymphoma treated with mogamulizumab monotherapy and mogamulizumab plus etoposide combined therapy: A real-world case series
    Amagai, Ryo
    Kambayashi, Yumi
    Ohuchi, Kentaro
    Furudate, Sadanori
    Hashimoto, Akira
    Asano, Yoshihide
    Fujimura, Taku
    [J]. DERMATOLOGIC THERAPY, 2022, 35 (11)
  • [5] Asokan Ishan, 2022, JAAD Case Rep, V20, P44, DOI 10.1016/j.jdcr.2021.11.022
  • [6] Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma
    Beygi, Sara
    Duran, George E.
    Fernandez-Pol, Sebastian
    Rook, Alain H.
    Kim, Youn H.
    Khodadoust, Michael S.
    [J]. BLOOD, 2022, 139 (26) : 3732 - 3736
  • [7] Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sezary syndrome: A multicentre, retrospective, real-world French study
    Beylot-Barry, M.
    Quereux, G.
    Nardin, C.
    Duval-Modeste, A. -b.
    Dereure, O.
    Dalac-Rat, S.
    Dobos, G.
    Pham-Ledard, A.
    Ram-Wolff, C.
    D'Incan, M.
    Grange, F.
    Braniste, V.
    Bagot, M.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, : 1777 - 1784
  • [8] Association of autoimmunity and long-term complete remission in patients with Sezary syndrome treated with mogamulizumab
    Bonnet, P.
    Battistella, M.
    Roelens, M.
    Ram-Wolff, C.
    Herms, F.
    Frumholtz, L.
    Bouaziz, J. -D.
    Brice, P.
    Moins-Teisserenc, H.
    Bagot, M.
    de Masson, A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (02) : 419 - 420
  • [9] Leucoderma associated with flares of erythrodermic cutaneous T-cell lymphomas: four cases
    Bouloc, A
    Grange, F
    Delfau-Larue, MH
    Dieng, MT
    Tortel, MC
    Avril, MF
    Revuz, J
    Bagot, M
    Wechsler, J
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2000, 143 (04) : 832 - 836
  • [10] Breen Ilana D, 2021, JAAD Case Rep, V9, P24, DOI 10.1016/j.jdcr.2020.12.035